Pacific Biosciences
PACB
81 hedge funds and large institutions have $184M invested in Pacific Biosciences in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 6 closing their positions.
199% more call options, than puts
Call options by funds: $454K | Put options by funds: $152K
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
147% more capital invested
Capital invested by funds: $74.4M → $184M (+$109M)
106% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 18
14% more funds holding
Funds holding: 71 → 81 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$7.92M |
| 2 |
Millennium Management
New York
|
+$5.81M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.28M |
| 4 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$1.07M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$737K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$3.45M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.04M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$972K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$788K |
| 5 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$506K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Royal Bank of Canada
Toronto,
Ontario, Canada
| $11K | – | – | – |
|
77
Barclays
London,
United Kingdom
| $9K | -$118K | -33,936 | -95% |
|
78
BlackRock
New York
| $6K | +$3.92K | +1,128 | New |
|
|
U
79
UBS
Zurich,
Switzerland
| $4K | – | – | – |
|
80
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
81
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $8 | +$1.53K | +440 | +46% |
|
|
MHP
82
Manatuck Hill Partners
Westport,
Connecticut
| – | -$506K | -200,000 | Closed |
|
|
MA
83
MUFG Americas
New York
| – | -$237K | -94,100 | Closed |
|
|
FMBTD
84
First Midwest Bank Trust Division
Joliet,
Illinois
| – | -$107K | -42,467 | Closed |
|
85
Principal Financial Group
Des Moines,
Iowa
| – | -$52K | -20,519 | Closed |
|
|
NI
86
Numeric Investors
Boston,
Massachusetts
| – | -$46K | -18,200 | Closed |
|
|
CA
87
CapWealth Advisors
Franklin,
Tennessee
| – | -$1K | -500 | Closed |
|
PACB Hedge Fund Activity: Q3 2013 in Review
81 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2013, worth a combined $184M — up 147% from $74.4M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PACB positions and 6 closed out — a net gain of 11 holders — while 37 added to existing stakes and 18 trimmed.
The largest buyer was Maverick Capital, adding an estimated $7.92M. The largest seller was Visium Asset Management, cutting an estimated $3.45M.
- 81 institutional investors held Pacific Biosciences (PACB) as of Q3 2013, up from 71 in Q2 2013.
- Funds reported $184M of Pacific Biosciences stock for Q3 2013, up 147% quarter-over-quarter.
- 17 funds opened new Pacific Biosciences positions in Q3 2013 and 6 closed out, a net change of +11 holders.
- The largest Pacific Biosciences buyer in Q3 2013 was Maverick Capital, an estimated $7.92M added.
- The largest Pacific Biosciences seller in Q3 2013 was Visium Asset Management, an estimated $3.45M sold.
Based on aggregated 13F filings for Q3 2013.